^
Association details:
| Biomarker: | IRF8 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Yescarta (axicabtagene ciloleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Resistant |
Evidence:
Source:
Title:
006 | DETERMINANTS OF RESISTANCE TO ENGINEERED T-CELL THERAPIES TARGETING CD19 IN LYMPHOMA
Published date:
06/09/2021
Excerpt:
...analysis to patients receiving Axicabtagene Ciloleucel (axi-cel) to identify determinants of resistance...We identified 100.5 mutations/case, which was similar to a cohort of 136 untreated DLBCL patients....Additionally, genomic alterations in several genes, including CD19, CD58, PAX5 and IRF8 are associated with inferior outcomes.
